{
  "symbol": "REGN",
  "year": 2024,
  "Period": "Y2024",
  "report_type": "K10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.2612,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.372
  },
  "top_positive": [
    {
      "sent": "These statements concern, and these risks and uncertainties include, among others: \u2022 the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Products\") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Product Candidates\") and research and clinical programs now underway or planned, including without limitation those discussed or referenced in this report, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; \u2022 the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; \u2022 safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; \u2022 the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those discussed or referenced in this report; \u2022 the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; \u2022 ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; \u2022 determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; \u2022 competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; \u2022 uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; \u2022 our ability to manufacture and manage supply chains for multiple products and product candidates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
      "score": 0.9944
    },
    {
      "sent": "General Subject Matter Class Expiration Dupixent (continued) JP 6,306,588 Methods of Treatment August 20, 2033 \u2013 August 29, 2034 (d) JP 6,353,838 Methods of Treatment September 4, 2033 JP 6,673,840 Methods of Treatment February 20, 2035 JP 6,463,351 Methods of Treatment June 20, 2034 \u2013 September 2, 2035 (d) JP 6,861,630 Methods of Treatment November 13, 2035 JP 7,164,530 Methods of Treatment September 21, 2037 JP 7,216,122 Methods of Treatment November 13, 2035 JP 7,216,157 Methods of Treatment August 20, 2033 JP 7,256,231 Methods of Treatment September 4, 2033 JP 7,315,545 Methods of Treatment October 29, 2038 JP 7,343,547 Methods of Treatment February 20, 2035 Libtayo cemiplimab US 9,987,500 Composition of Matter September 18, 2035 US 10,737,113 Composition of Matter April 10, 2035 US 11,603,407 Formulation March 21, 2038 US 10,457,725 Methods of Treatment May 12, 2037 US 11,292,842 Methods of Treatment July 18, 2038 US 11,505,600 Methods of Treatment July 2, 2038 EP 3097119 Composition of Matter January 23, 2035 EP 3606504 Formulation March 23, 2038 EP 3455258 Methods of Treatment May 12, 2037 EP 3932951 Methods of Treatment May 12, 2037 JP 6,425,730 Composition of Matter January 23, 2035 \u2013 March 15, 2039 (d) JP 6,711,883 Composition of Matter January 23, 2035 \u2013 August 13, 2037 (d) JP 7,174,009 Composition of Matter January 23, 2035 \u2013 March 9, 2035 (d) JP 7,229,171 Formulation March 23, 2038 JP 6,999,577 Methods of Treatment May 12, 2037 JP 7,054,680 Methods of Treatment May 12, 2037 JP 7,240,512 Methods of Treatment May 25, 2041 (a) See Note 16 to our Consolidated Financial Statements for information regarding inter partes review and post-grant review petitions filed in the U.S.",
      "score": 0.9908
    },
    {
      "sent": "General Subject Matter Class Expiration Dupixent (continued) JP 6,306,588 Methods of Treatment August 20, 2033 \u2013 August 29, 2034 (d) JP 6,353,838 Methods of Treatment September 4, 2033 JP 6,673,840 Methods of Treatment February 20, 2035 JP 6,463,351 Methods of Treatment June 20, 2034 \u2013 September 2, 2035 (d) JP 6,861,630 Methods of Treatment November 13, 2035 JP 7,164,530 Methods of Treatment September 21, 2037 JP 7,216,122 Methods of Treatment November 13, 2035 JP 7,216,157 Methods of Treatment August 20, 2033 JP 7,256,231 Methods of Treatment September 4, 2033 JP 7,315,545 Methods of Treatment October 29, 2038 JP 7,343,547 Methods of Treatment February 20, 2035 Libtayo cemiplimab US 9,987,500 Composition of Matter September 18, 2035 US 10,737,113 Composition of Matter April 10, 2035 US 11,603,407 Formulation March 21, 2038 US 10,457,725 Methods of Treatment May 12, 2037 US 11,292,842 Methods of Treatment July 18, 2038 US 11,505,600 Methods of Treatment July 2, 2038 EP 3097119 Composition of Matter January 23, 2035 EP 3606504 Formulation March 23, 2038 EP 3455258 Methods of Treatment May 12, 2037 EP 3932951 Methods of Treatment May 12, 2037 JP 6,425,730 Composition of Matter January 23, 2035 \u2013 March 15, 2039 (d) JP 6,711,883 Composition of Matter January 23, 2035 \u2013 August 13, 2037 (d) JP 7,174,009 Composition of Matter January 23, 2035 \u2013 March 9, 2035 (d) JP 7,229,171 Formulation March 23, 2038 JP 6,999,577 Methods of Treatment May 12, 2037 JP 7,054,680 Methods of Treatment May 12, 2037 JP 7,240,512 Methods of Treatment May 25, 2041 (a) See Note 16 to our Consolidated Financial Statements for information regarding inter partes review and post-grant review petitions filed in the U.S.",
      "score": 0.9908
    }
  ],
  "top_negative": [
    {
      "sent": "Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.",
      "score": -0.9531
    },
    {
      "sent": "Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions.",
      "score": -0.9371
    }
  ],
  "forward_snippets": [
    "These statements concern, and these risks and uncertainties include, among others: \u2022 the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Products\") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Product Candidates\") and research and clinical programs now underway or planned, including without limitation those discussed or referenced in this report, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; \u2022 the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; \u2022 safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; \u2022 the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those discussed or referenced in this report; \u2022 the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; \u2022 ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; \u2022 determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; \u2022 competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; \u2022 uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; \u2022 our ability to manufacture and manage supply chains for multiple products and product candidates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "Our core business strategy is \ndidates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "Refer\nling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "(d) The Company is solely responsible \nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "Intellia will lead the design of the editing methodology, we will lead the design of the targeted viral vector delivery approach, and the parties share costs equally."
  ],
  "curated_text": "Symbol: REGN. Year: 2024. Period: Y2024. ReportType: K10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: These statements concern, and these risks and uncertainties include, among others: \u2022 the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Products\") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Product Candidates\") and research and clinical programs now underway or planned, including without limitation those discussed or referenced in this report, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; \u2022 the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; \u2022 safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; \u2022 the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those discussed or referenced in this report; \u2022 the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; \u2022 ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; \u2022 determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; \u2022 competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; \u2022 uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; \u2022 our ability to manufacture and manage supply chains for multiple products and product candidates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. General Subject Matter Class Expiration Dupixent (continued) JP 6,306,588 Methods of Treatment August 20, 2033 \u2013 August 29, 2034 (d) JP 6,353,838 Methods of Treatment September 4, 2033 JP 6,673,840 Methods of Treatment February 20, 2035 JP 6,463,351 Methods of Treatment June 20, 2034 \u2013 September 2, 2035 (d) JP 6,861,630 Methods of Treatment November 13, 2035 JP 7,164,530 Methods of Treatment September 21, 2037 JP 7,216,122 Methods of Treatment November 13, 2035 JP 7,216,157 Methods of Treatment August 20, 2033 JP 7,256,231 Methods of Treatment September 4, 2033 JP 7,315,545 Methods of Treatment October 29, 2038 JP 7,343,547 Methods of Treatment February 20, 2035 Libtayo cemiplimab US 9,987,500 Composition of Matter September 18, 2035 US 10,737,113 Composition of Matter April 10, 2035 US 11,603,407 Formulation March 21, 2038 US 10,457,725 Methods of Treatment May 12, 2037 US 11,292,842 Methods of Treatment July 18, 2038 US 11,505,600 Methods of Treatment July 2, 2038 EP 3097119 Composition of Matter January 23, 2035 EP 3606504 Formulation March 23, 2038 EP 3455258 Methods of Treatment May 12, 2037 EP 3932951 Methods of Treatment May 12, 2037 JP 6,425,730 Composition of Matter January 23, 2035 \u2013 March 15, 2039 (d) JP 6,711,883 Composition of Matter January 23, 2035 \u2013 August 13, 2037 (d) JP 7,174,009 Composition of Matter January 23, 2035 \u2013 March 9, 2035 (d) JP 7,229,171 Formulation March 23, 2038 JP 6,999,577 Methods of Treatment May 12, 2037 JP 7,054,680 Methods of Treatment May 12, 2037 JP 7,240,512 Methods of Treatment May 25, 2041 (a) See Note 16 to our Consolidated Financial Statements for information regarding inter partes review and post-grant review petitions filed in the U.S. General Subject Matter Class Expiration Dupixent (continued) JP 6,306,588 Methods of Treatment August 20, 2033 \u2013 August 29, 2034 (d) JP 6,353,838 Methods of Treatment September 4, 2033 JP 6,673,840 Methods of Treatment February 20, 2035 JP 6,463,351 Methods of Treatment June 20, 2034 \u2013 September 2, 2035 (d) JP 6,861,630 Methods of Treatment November 13, 2035 JP 7,164,530 Methods of Treatment September 21, 2037 JP 7,216,122 Methods of Treatment November 13, 2035 JP 7,216,157 Methods of Treatment August 20, 2033 JP 7,256,231 Methods of Treatment September 4, 2033 JP 7,315,545 Methods of Treatment October 29, 2038 JP 7,343,547 Methods of Treatment February 20, 2035 Libtayo cemiplimab US 9,987,500 Composition of Matter September 18, 2035 US 10,737,113 Composition of Matter April 10, 2035 US 11,603,407 Formulation March 21, 2038 US 10,457,725 Methods of Treatment May 12, 2037 US 11,292,842 Methods of Treatment July 18, 2038 US 11,505,600 Methods of Treatment July 2, 2038 EP 3097119 Composition of Matter January 23, 2035 EP 3606504 Formulation March 23, 2038 EP 3455258 Methods of Treatment May 12, 2037 EP 3932951 Methods of Treatment May 12, 2037 JP 6,425,730 Composition of Matter January 23, 2035 \u2013 March 15, 2039 (d) JP 6,711,883 Composition of Matter January 23, 2035 \u2013 August 13, 2037 (d) JP 7,174,009 Composition of Matter January 23, 2035 \u2013 March 9, 2035 (d) JP 7,229,171 Formulation March 23, 2038 JP 6,999,577 Methods of Treatment May 12, 2037 JP 7,054,680 Methods of Treatment May 12, 2037 JP 7,240,512 Methods of Treatment May 25, 2041 (a) See Note 16 to our Consolidated Financial Statements for information regarding inter partes review and post-grant review petitions filed in the U.S. Top negative sentences: Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems. Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions. Forward-looking snippets: These statements concern, and these risks and uncertainties include, among others: \u2022 the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Products\") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, \"Regeneron's Product Candidates\") and research and clinical programs now underway or planned, including without limitation those discussed or referenced in this report, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs; \u2022 the likelihood and timing of achieving any of our anticipated development milestones referenced in this report; \u2022 safety issues resulting from the administration of Regeneron's Products and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; \u2022 the likelihood, timing, and scope of possible regulatory approval and commercial launch of our late-stage product candidates and new indications for Regeneron's Products, including without limitation those discussed or referenced in this report; \u2022 the extent to which the results from the research and development programs conducted by us and/or our collaborators may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; \u2022 ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; \u2022 determinations by regulatory and administrative governmental authorities which may delay or restrict our ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; \u2022 competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; \u2022 uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties on the commercial success of Regeneron's Products and Regeneron's Product Candidates; \u2022 our ability to manufacture and manage supply chains for multiple products and product candidates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. Our core business strategy is \ndidates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. Refer\nling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. (d) The Company is solely responsible \nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 16 to our Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 16 to our Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. Intellia will lead the design of the editing methodology, we will lead the design of the targeted viral vector delivery approach, and the parties share costs equally."
}